The efficacy of Russia’s corona virus vaccine Sputnik V has been reported to be 91.4 percent. The company gave this information in a statement released on Monday. The statement said that this data is based on the final control point analysis of the data 21 days after the first dose of the vaccine.
Singapore has approved the vaccine for Kovid-19 developed by American pharmaceutical company Pfizer and German company BioNotech. The Prime Minister of the country, Li Shen Long, announced this on Monday and said that the first batch of vaccines will be received by the end of this month.
Regarding the status of Kovid-19 in Singapore, Prime Minister Li Shen Long said in a televised message that the Health Department authority approved the Pfizer-BioNotech vaccine after studying scientific evidence and clinical trial data.
This news of Sputnik-V being effective has come at a time when there is talk of starting its production in India. India’s drug company Hetero has tied up with the Russian Direct Investment Fund (RDIF) for Vaccine Sputnik-V. It is being told that 100 million doses of vaccine will be prepared in India every year.
In fact, Russia’s Savren Wealth Fund said that Sputnik-V is intended to start production in 2021. Currently, the third phase of this vaccine trial is going on in Belarus, UAE, Venezuela and other countries. At the same time, the second phase and third phase trials are going on in India. More than 50 countries have requested Russia for Sputnik-V. It is being told that the vaccine is to be produced in China, Brazil, South Korea and other countries besides India to supply in the global market.
